<p>This is a single-arm, non-randomized, phase 2 trial (<a href="https://clinicaltrials.gov/ct2/results?term=NCT03104439">NCT03104439</a>) combining radiation, ipilimumab and nivolumab in patients with metastatic MSS Colorectal Cancer (CRC; n=40) and Pancreatic Ductal Adenocarcinoma Cancer (PDAC; n=25). Patients were previously treated population, and the primary endpoint was disease control rate. Pre- and post-treatment samples were subjected to RNA sequencing and whole exome sequencing. The primary data is shared via GEO and dbGaP at <a href="https://www.ncbi.nlm.nih.gov/">National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH)</a>.</p>

Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable    (MSS) and Microsatellite Instable (MSI) High Colorectal and Pancreatic    Cancer

19 variables across Demographics, Race and Ethnicity

Variables — phs002545 — Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable    (MSS) and Microsatellite Instable (MSI) High Colorectal and Pancreatic    Cancer

Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instable (MSI) High Colorectal and Pancreatic Cancer

Demographics (3)

Race and Ethnicity (1)

Other (15)